Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of “Moderate Buy” by Brokerages

Elanco Animal Health Incorporated (NYSE:ELAN) has been given an average recommendation of “Moderate Buy” by the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $23.7778.

ELAN has been the subject of several recent analyst reports. Stifel Nicolaus upped their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. UBS Group upped their price objective on shares of Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. JPMorgan Chase & Co. raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $18.00 to $24.00 in a research note on Tuesday, October 7th. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday.

Insider Activity at Elanco Animal Health

In related news, insider Rajeev A. Modi purchased 4,500 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were purchased at an average price of $21.33 per share, with a total value of $95,985.00. Following the completion of the purchase, the insider owned 123,082 shares in the company, valued at $2,625,339.06. This represents a 3.79% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jeffrey N. Simmons acquired 22,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average cost of $21.75 per share, for a total transaction of $478,500.00. Following the completion of the transaction, the chief executive officer directly owned 167,000 shares in the company, valued at $3,632,250. This represents a 15.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have bought 43,450 shares of company stock valued at $937,883. Corporate insiders own 0.89% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ELAN. Hsbc Holdings PLC boosted its stake in Elanco Animal Health by 434.2% in the 2nd quarter. Hsbc Holdings PLC now owns 126,334 shares of the company’s stock valued at $1,801,000 after purchasing an additional 102,686 shares during the period. Norges Bank bought a new position in Elanco Animal Health during the 2nd quarter worth $12,502,000. Comerica Bank lifted its holdings in shares of Elanco Animal Health by 46.4% during the first quarter. Comerica Bank now owns 49,680 shares of the company’s stock worth $522,000 after buying an additional 15,754 shares in the last quarter. Equitable Trust Co. boosted its position in shares of Elanco Animal Health by 65.5% in the second quarter. Equitable Trust Co. now owns 248,108 shares of the company’s stock valued at $3,543,000 after acquiring an additional 98,172 shares during the period. Finally, Callan Family Office LLC boosted its position in shares of Elanco Animal Health by 239.0% in the second quarter. Callan Family Office LLC now owns 166,198 shares of the company’s stock valued at $2,373,000 after acquiring an additional 117,174 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 0.7%

ELAN opened at $22.38 on Friday. The firm has a 50 day simple moving average of $22.07 and a 200 day simple moving average of $18.58. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $23.70. The company has a market cap of $11.12 billion, a price-to-earnings ratio of 373.06, a price-to-earnings-growth ratio of 3.42 and a beta of 1.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The firm’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, sell-side analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.